bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)

Reference No. 3414

Appraisal information

bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) 50 mg/200 mg/25 mg film-coated tablet

Company:	Gilead Sciences Ltd
BNF category:	Infections
NMG meeting date:	10/10/2018
AWMSG meeting date:	14/11/2018

Submission Type:	Full Submission
Status:	In progress
Advice No:	Not available
Ratification by Welsh Government:	Not available

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

Indication

Treatment of adults infected with human immunodeficiency virus 1 without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir

Preliminary Appraisal Recommendation (PAR)

Download

bictegravir (Biktarvy) 3414 PAR

Company Response to the Preliminary Appraisal Recommendation (CR PAR)

Download

bictegravir (Biktarvy) 3414 CR PAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

bictegravir (Biktarvy) 3414 ASAR